Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-26 @ 10:37 AM
Ignite Modification Date: 2025-12-26 @ 10:37 AM
NCT ID: NCT02072928
Description: All enrolled patients were used to assess adverse events and serious adverse events.
Frequency Threshold: 5
Time Frame: None
Study: NCT02072928
Study Brief: Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
BOTOX® Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice. None None 4 55 0 55 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Epididymitis SYSTEMATIC_ASSESSMENT Reproductive system and breast disorders MedDRA version 18.1 View
Pyelonephritis SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA version 18.1 View
Progression of MS SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA version 18.1 View
Erysipelas SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA version 18.1 View
Other Events(If Any):